Quality of life

Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

Retrieved on: 
木曜日, 4月 18, 2024
Eurostat, Diagnosis, Civil service commission, X-ray, Growth, Medicine, Disease, Patient, Ageing, Committee, Knowledge, Tissue, Neoplasm, Light, Cutaneous T-cell lymphoma, Regulation, Cancer, EMA, IRIS, Quality of life, Reactive oxygen species, Lymph, CTCL, Clinical trial, European, Skin, COMP, Oxygen, European Commission, Immune system, Safety, Carmustine, Alfa, Marketing, Lymphatic system, Pharmaceutical industry

Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

Key Points: 


Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
水曜日, 4月 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

Implenia wins contract for key section of Bremen’s motorway ring-road

Retrieved on: 
水曜日, 4月 10, 2024
EUR, Lean construction, Noise, DEGES, SIX Swiss Exchange, Quality of life, FTE, Bremen Airport, CHF, Corporate communication, Large

Working in a joint venture with Johann Bunte Bauunternehmen, the Group is building section 2/2 of the A 281 motorway.

Key Points: 
  • Working in a joint venture with Johann Bunte Bauunternehmen, the Group is building section 2/2 of the A 281 motorway.
  • The new motorway link will significantly improve the traffic situation in the whole of north-west Germany.
  • The joint venture contract includes the construction of a 1.7 km section of the motorway bypass between the Neuenlander Ring and the Kattenturmer Heerstrasse near Bremen Airport.
  • Support walls with bored pile foundations are being built first to take the motorway up to the bridge.

EQS-News: ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease

Retrieved on: 
水曜日, 4月 10, 2024
Cell, Bone marrow, Disease, Transplant, Risk, Clinic, Patient, Gastrointestinal tract, Mortality, Haematopoietic system, Leukemia, Quality of life, Graft-versus-host disease, Clinical trial, Skin, Safety, CSO, Liver, Acute leukemia, Vaccine

GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.

Key Points: 
  • GvHD is a severe and potentially life-threatening complication that can arise after an allogeneic haematopoietic stem cell transplantation and affects about 50 % of recipients.
  • GvHD occurs when the stem cell donor’s T cells attack the patient’s tissues, leading to a range of symptoms that can affect the skin, gastrointestinal tract, and liver.
  • Prof. Dr. Andrea Tüttenberg, CEO of ActiTrexx, said: “GvHD can lead to life-long symptoms for the patient and is a major cause for the high mortality rate of blood stem cell transplantation.
  • Ten patients who have recently received a blood stem cell transplantation as treatment for leukemia will receive a single treatment with Actileucel.

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on: 
月曜日, 4月 8, 2024
CASA, Toothpaste, Head, Confusion, Tooth brushing, EFP, Journal of Clinical Periodontology, Patient, Quality of life, Complutense University of Madrid, UCM, Therapy, Dental, Oral hygiene, Etiology, United States of Europe, Risk, Education, Gingivitis, Treatment, Recurrence, Dentistry, Prevalence, Disease, Clinical, White paper, Public, Knowledge, Research, University, Overalls, University College London, Mouthwash, Dentist, Molina Healthcare, Health, Motivation, Incidence, Physician, British Dental Journal, Inflammation, Pharmacist, Plaque, Systematic review, Bleeding, S3, Meta-analysis

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points: 
  • This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
  • "Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
  • As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
  • J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
    * Chapple I, Time to take gum disease seriously.

Real Estate Mogul Daniel Neiditch Teams up with Sports Legends John Starks, Darryl Strawberry and Tommy Devito for a Day of Charity in New York

Retrieved on: 
木曜日, 3月 14, 2024
Learning, Sport, New York Giants, Intelligence, Human, Child, Quality of life, Athlete, Strawberry, New York Yankees, Spectrum, New York Mets, Typesetting

He believes that learning disabilities are not indicative of a child's intelligence but rather a neurological condition that can impede traditional learning processes.

Key Points: 
  • He believes that learning disabilities are not indicative of a child's intelligence but rather a neurological condition that can impede traditional learning processes.
  • John Starks, a Knicks legend, is well-known for his foundation, which provides financial aid to college-bound high school seniors.
  • Darryl Strawberry, a baseball icon, focuses on improving the quality of life for individuals affected by autism.
  • The day began with a friendly basketball match between Neiditch and Starks, showcasing their competitive spirit and mutual respect.

North Bay Village Advances with Approval of 10 Real Estate Developments

Retrieved on: 
月曜日, 3月 18, 2024
Football, Quality of life, Supermarket, Daro District, Sport, Restaurant, Argentine Football Association, Local government

As localities of North Bay Village, Andy Daro and The Daro team lead the way in expertise for the promising new developments and current resale opportunities of the neighborhood.

Key Points: 
  • As localities of North Bay Village, Andy Daro and The Daro team lead the way in expertise for the promising new developments and current resale opportunities of the neighborhood.
  • The Daro Team sets an exceptionally high standard for efficiency in Southeast Florida's luxury real estate market and are recognized as part of the top 100 real estate teams in Florida.
  • The vision for North Bay Village goes beyond just constructing new buildings; plans involve replacing old flailing structures with vibrant, high-end developments.
  • With the expertise of Andy Daro and team, together with the support from the local government, North Bay Village is set to become a next-generation cityscape.

APEL Biomedical Technology Innovation and Translational Commercial Laboratory Officially Opens

Retrieved on: 
水曜日, 3月 13, 2024
Yee, New Territories, Nutrition, Health, Technology transfer, Quality of life, HKSAR, Hygiene, QPP, Corporation, Certification, Environment, Innovation, Biotechnology, Partnership, Biomedical technology, Biological engineering, Translational research, Silk, Knowledge, Research, SGS, Lifestar, Translation, Science park, Sustainability, Pet, Government, Growth, Greater, Perception, PET, HKSTP, APEL, Life, Hong Kong Science Park, Toxicology, Division, Medical imaging

Dr. Grace Lau, Head of Institute for Translational Research of Hong Kong Science and Technology Parks Corporation (HKSTP) stated, "It is great to see the official opening of APEL Laboratory and the successful transformation of scientific research and technology into commercial products.

Key Points: 
  • Dr. Grace Lau, Head of Institute for Translational Research of Hong Kong Science and Technology Parks Corporation (HKSTP) stated, "It is great to see the official opening of APEL Laboratory and the successful transformation of scientific research and technology into commercial products.
  • We have attracted numerous biomedical innovation and technology enterprises, covering areas such as pharmaceuticals, medical devices, diagnostics, and traditional Chinese medicine.
  • Today, we are delighted to have officially established our presence in Hong Kong Science Park with the opening of the Biomedical Technology Innovation and Translational Commercial Laboratory.
  • The pet industry ecosystem is vibrant, and today, during the inauguration ceremony of the APEL Biomedical Technology Innovation and Translational Commercial Laboratory, APEL also organized a panel discussion on the future opportunities and transformations in the pet industry.

Olansky Dermatology & Aesthetics welcomes physician assistant, expands hours

Retrieved on: 
火曜日, 4月 9, 2024
Psoriasis, Skin cancer, Patient, Mohs surgery, Aesthetics, Quality of life, Suite, Dermatology, Acne, Family

ATLANTA, April 09, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics –Georgia’s top-rated dermatology practice– welcomes physician assistant Kathryn “Katie” Shea to its Buckhead location.

Key Points: 
  • ATLANTA, April 09, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics –Georgia’s top-rated dermatology practice– welcomes physician assistant Kathryn “Katie” Shea to its Buckhead location.
  • This addition to the practice’s acclaimed staff allows Olansky Dermatology & Aesthetics the ability to offer new, expanded hours at its Buckhead location, a first for Atlanta area dermatology.
  • She has extensive experience in dermatology and urgent care medicine, and she is a member of the Georgia Association of Physician Assistants, American Academy of Physician Assistants, and Georgia Dermatology Physician Assistants.
  • “We strive to offer our patients the best providers possible,” says Dr. Jodi Ganz, physician partner at Olansky Dermatology & Aesthetics, “By growing our staff, it allows us to better meet patients where they are and provide additional hours for better flexibility.”
    Olansky Dermatology & Aesthetics is your dermatology solution.

Current constipation medications don't provide relief for some patients with Chronic Idiopathic Constipation, per Gastroenterologist survey

Retrieved on: 
火曜日, 4月 9, 2024
Adverse, Laxative, Gastrointestinal disease, Defecation, Patient, Human, American Journal, Weight loss, Constipation, News, Quality of life, Vibrant consonant, Hope, Invention, FDA

The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.

Key Points: 
  • The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.
  • Disrupting the U.S. $4.6 billion constipation treatment market, Vibrant Gastro’s first-in-class technology offers providers and patients with a new, non-pharmaceutical alternative to address this issue.
  • Patients track the progress of the treatment on their phone with an app to increase compliance, consistency and to monitor results.
  • A study presented at Digestive Disease Week in 2023 found significant symptomatic relief in patients and a substantially improved quality of life.